City

Clinical trials near Indianapolis, United States

Active studies with a listed research site in Indianapolis, United States.

19active studies

7recruiting now

28countries represented

47largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Psoriasis, Overweight or ObesityCondition

TirzepatideTreatment

United States39 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06857942See eligibility →

Recruiting nowPhase 3

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, Placebo cagrilintideTreatment

Greece, Hungary36 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07745504See eligibility →

Recruiting nowPhase 2

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

Type 1 Diabetes, ObesityCondition

MetforminTreatment

United States1 locations

Heba M. IsmailSponsor

Updated 2026-08-21 · NCT05414409See eligibility →

Recruiting nowNot applicable

A Sensory Strategy to Cut Sugary Beverages in African/American and Latine Adolescents

Obesity, Adolescent, Dietary SugarsCondition

Unsweetened Sparkling Water Replacement, Progressively Reduced Sugar Beverage ReplacementTreatment

United States3 locations

Nana Gletsu MillerSponsor

Updated 2026-08-06 · NCT07223151See eligibility →

Recruiting nowPhase 4

Fibrosis Lessens After Metabolic Surgery

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver DiseaseCondition

Metabolic surgery, Incretin-Based TherapyTreatment

Brazil, Canada22 locations

The Cleveland ClinicSponsor

Updated 2026-07-31 · NCT06374875See eligibility →

Recruiting nowPhase 2

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

ObesityCondition

NNC0662-0419, SemaglutideTreatment

Puerto Rico, United States25 locations

Novo Nordisk A/SSponsor

Updated 2026-07-10 · NCT07639021See eligibility →

Recruiting nowNot applicable

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

Gestational Diabetes, Pregnancy, High RiskCondition

Intensive glycemic targets, Standard glycemic targetsTreatment

United States5 locations

Indiana UniversitySponsor

Updated 2026-06-24 · NCT05124808See eligibility →

Opening soonPhase 2

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Atherosclerosis, Cardiovascular DiseaseCondition

Clazakizumab, PlaceboTreatment

Argentina, Japan47 locations

Eli Lilly and CompanySponsor

Updated 2026-08-25 · NCT07783802See eligibility →

Opening soonPhase 3

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Overweight, ObesityCondition

Zenagamtide, SemaglutideTreatment

United States43 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07668414See eligibility →

Opening soonPhase 3

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Overweight, ObesityCondition

zenagamtide, PlaceboTreatment

United States37 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07720271See eligibility →

Invitation onlyNot applicable

Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes

ObesityCondition

Incretin-based therapies (GLP-1 and GLP-1/GIP)Treatment

United States1 locations

Indiana UniversitySponsor

Updated 2026-06-10 · NCT07640139See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Obesity, OverweightCondition

Cagrilintide, PlaceboTreatment

Argentina, Australia40 locations

Novo Nordisk A/SSponsor

Updated 2026-08-06 · NCT07220642See eligibility →

Active, not recruitingPhase 3

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

ObesityCondition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

United States46 locations

Novo Nordisk A/SSponsor

Updated 2026-07-24 · NCT07011667See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

ObesityCondition

Ribupatide, PlaceboTreatment

United States35 locations

KaileraSponsor

Updated 2026-07-15 · NCT07458269See eligibility →

Active, not recruitingPhase 2

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Overweight, ObesityCondition

Tirzepatide, PlaceboTreatment

Austria, Canada27 locations

Eli Lilly and CompanySponsor

Updated 2026-05-08 · NCT05536804See eligibility →

Active, not recruitingNot applicable

Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis

NASH - Nonalcoholic Steatohepatitis, Cirrhosis, LiverCondition

Dietary consult for participants in the ketogenic diet arm, Dietary consult for participants in the standard of care armTreatment

United States1 locations

Indiana UniversitySponsor

Updated 2026-04-17 · NCT04383951See eligibility →

Active, not recruitingPhase 2

Taldefgrobep Alfa in Adults With Overweight and Obesity

Obesity, OverweightCondition

Taldefgrobep Alfa, PlaceboTreatment

United States20 locations

Biohaven Therapeutics Ltd.Sponsor

Updated 2026-03-20 · NCT07281495See eligibility →

Active, not recruitingNot applicable

Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide

Obesity, Weight Change TrajectoryCondition

Revita Duodenal Mucosal Resurfacing (DMR), ShamTreatment

United States32 locations

Fractyl Health Inc.Sponsor

Updated 2026-03-03 · NCT06484114See eligibility →

Active, not recruitingNot applicable

The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)

ObesityCondition

AGBSTreatment

United States17 locations

Allurion TechnologiesSponsor

Updated 2024-10-26 · NCT05368259See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Indianapolis, United States

Current studies

Related cities